Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

High Risk Supratentorial PNET Clinical Trial

Official title: Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET

Status Completed

Clinical Trial Summary

The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• High Risk Supratentorial PNET
• Medulloblastoma
• Metastatic Medulloblastoma
• Metastatic PNET
• Neuroectodermal Tumors, Primitive

• NCT number: NCT01542736
• Study type: Interventional
• Source: University of Colorado, Denver
• Status: Completed
• Phase: Phase 2
• Start date: May 2007
• Completion date: September 2020